605 related articles for article (PubMed ID: 23881427)
1. Extending survival with the use of targeted therapy in the treatment of hepatocellular carcinoma.
Gish RG; Finn RS; Marrero JA
Clin Adv Hematol Oncol; 2013 Apr; 11 Suppl 5():1-22; quiz 2 p following p22. PubMed ID: 23881427
[TBL] [Abstract][Full Text] [Related]
2. Extending survival with the use of targeted therapy in the treatment of hepatocellular carcinoma.
Gish RG; Finn RS; Marrero JA
Gastroenterol Hepatol (N Y); 2013 Apr; 9(4 Suppl 2):1-24. PubMed ID: 24872793
[TBL] [Abstract][Full Text] [Related]
3. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.
Cho JY; Paik YH; Lim HY; Kim YG; Lim HK; Min YW; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
Liver Int; 2013 Jul; 33(6):950-7. PubMed ID: 23601249
[TBL] [Abstract][Full Text] [Related]
4. Treatment of hepatocellular carcinoma combining sorafenib and transarterial locoregional therapy: state of the science.
Weintraub JL; Salem R
J Vasc Interv Radiol; 2013 Aug; 24(8):1123-34. PubMed ID: 23562168
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization.
Ogasawara S; Chiba T; Ooka Y; Kanogawa N; Motoyama T; Suzuki E; Tawada A; Kanai F; Yoshikawa M; Yokosuka O
Oncology; 2014; 87(6):330-41. PubMed ID: 25227534
[TBL] [Abstract][Full Text] [Related]
6. Treatment of hepatocellular carcinoma: beyond international guidelines.
Colombo M; Sangiovanni A
Liver Int; 2015 Jan; 35 Suppl 1():129-38. PubMed ID: 25529098
[TBL] [Abstract][Full Text] [Related]
7. The Impact of Combined Transarterial Chemoembolization on the Overall Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib.
Chen L; Su H; Shao H; Xu K; Liang S; Liu J
Hepatogastroenterology; 2014 May; 61(131):802-8. PubMed ID: 26176077
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma.
Cammà C; Cabibbo G; Petta S; Enea M; Iavarone M; Grieco A; Gasbarrini A; Villa E; Zavaglia C; Bruno R; Colombo M; Craxì A; ;
Hepatology; 2013 Mar; 57(3):1046-54. PubMed ID: 23299720
[TBL] [Abstract][Full Text] [Related]
9. Intermediate hepatocellular carcinoma: current treatments and future perspectives.
Dufour JF; Bargellini I; De Maria N; De Simone P; Goulis I; Marinho RT
Ann Oncol; 2013 Apr; 24 Suppl 2():ii24-9. PubMed ID: 23715940
[TBL] [Abstract][Full Text] [Related]
10. Is the efficacy of sorafenib treatment in patients with hepatocellular carcinoma affected by age?
Cabibbo G; Maida M; Cammà C; Craxì A
Expert Rev Anticancer Ther; 2013 Dec; 13(12):1355-61. PubMed ID: 24224926
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib: the gold standard therapy in advanced hepatocellular carcinoma and beyond.
Gadaleta-Caldarola G; Divella R; Mazzocca A; Infusino S; Ferraro E; Filippelli G; Daniele A; Sabbà C; Abbate I; Brandi M
Future Oncol; 2015; 11(16):2263-6. PubMed ID: 26260805
[No Abstract] [Full Text] [Related]
12. Sorafenib treatment for recurrent hepatocellular carcinoma after liver transplantation.
Sotiropoulos GC; Nowak KW; Fouzas I; Vernadakis S; Kykalos S; Klein CG; Paul A
Transplant Proc; 2012 Nov; 44(9):2754-6. PubMed ID: 23146514
[TBL] [Abstract][Full Text] [Related]
13. The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib.
Wörns MA; Koch S; Niederle IM; Marquardt JU; Nguyen-Tat M; Gamstätter T; Schuchmann M; Schulze-Bergkamen H; Galle PR; Weinmann A
Dig Liver Dis; 2013 May; 45(5):408-13. PubMed ID: 23182599
[TBL] [Abstract][Full Text] [Related]
14. Extrahepatic spread of hepatocellular carcinoma.
Cabibbo G; Compilato D; Genco C; Campisi G
Panminerva Med; 2012 Dec; 54(4):313-22. PubMed ID: 23123584
[TBL] [Abstract][Full Text] [Related]
15. Treatment algorithm for intermediate and advanced stage hepatocellular carcinoma: Korea.
Choi JY
Oncology; 2011; 81 Suppl 1():141-7. PubMed ID: 22212948
[TBL] [Abstract][Full Text] [Related]
16. Surgical resection improves the survival of selected hepatocellular carcinoma patients in Barcelona clinic liver cancer stage C.
Wang JH; Kuo YH; Wang CC; Chen CL; Cheng YF; Hsu HC; Lu SN
Dig Liver Dis; 2013 Jun; 45(6):510-5. PubMed ID: 23218990
[TBL] [Abstract][Full Text] [Related]
17. Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trial.
Gandhi M; Choo SP; Thng CH; Tan SB; Low AS; Cheow PC; Goh AS; Tay KH; Lo RH; Goh BK; Wong JS; Ng DC; Soo KC; Liew WM; Chow PK;
BMC Cancer; 2016 Nov; 16(1):856. PubMed ID: 27821083
[TBL] [Abstract][Full Text] [Related]
18. Transarterial chemoembolization and sorafenib in patients with intermediate-stage hepatocellular carcinoma: time to enter routine clinical practice?
Sacco R; Antonucci M; Bargellini I; Marceglia S; Mismas V; Cabibbo G
Future Oncol; 2015; 11(17):2371-3. PubMed ID: 26270206
[No Abstract] [Full Text] [Related]
19. Adjuvant sorafenib after heptectomy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma patients.
Xia F; Wu LL; Lau WY; Huan HB; Wen XD; Ma KS; Li XW; Bie P
World J Gastroenterol; 2016 Jun; 22(23):5384-92. PubMed ID: 27340354
[TBL] [Abstract][Full Text] [Related]
20. Treatment of hepatocellular carcinoma: beyond international guidelines.
Sangiovanni A; Colombo M
Liver Int; 2016 Jan; 36 Suppl 1():124-9. PubMed ID: 26725909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]